23.7%); while the primary endpoint did not reach statistical significance, post hoc analyses suggested greater benefit among higher-risk donor livers, supporting the selective use of NMP in marginal grafts [ 21 ].
1
—
—
23.7%); while the primary endpoint did not reach statistical significance, post hoc analyses suggested greater benefit among higher-risk donor livers, supporting the selective use of NMP in marginal grafts [ 21 ].